Dossier assessment
Polatuzumab vedotin (DLBCL) – Benefit assessment according to § 35a Social Code Book V
Report documents
-
Extract of dossier assessment
Polatuzumab vedotin (DLBCL) – Benefit assessment according to § 35a Social Code Book V
-
Dossier assessment
Polatuzumab vedotin (DLBCL) – Benefit assessment according to § 35a Social Code Book V
Dossier assessment
Adults with previously untreated diffuse large B-cell lymphoma
Added benefit not proven
Press releases
Polatuzumab vedotin in untreated DLBCL: one step forward, two steps back
Additional information
Federal Joint Committee (G-BA)
2024-06-20 A G-BA decision was published.
Project details
- Project no.
- A23-141
- Commission
- Commission awarded on 21.12.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A23-141_en
Connected Projects
-
Dossier assessment
Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL) – Addendum to Project A23-141
Status: Commission completed